[go: up one dir, main page]

MX2010009920A - Compuestos de azaindol para tratamiento de trastornos del sistema nervioso central. - Google Patents

Compuestos de azaindol para tratamiento de trastornos del sistema nervioso central.

Info

Publication number
MX2010009920A
MX2010009920A MX2010009920A MX2010009920A MX2010009920A MX 2010009920 A MX2010009920 A MX 2010009920A MX 2010009920 A MX2010009920 A MX 2010009920A MX 2010009920 A MX2010009920 A MX 2010009920A MX 2010009920 A MX2010009920 A MX 2010009920A
Authority
MX
Mexico
Prior art keywords
nervous system
central nervous
compounds
treatment
system disorders
Prior art date
Application number
MX2010009920A
Other languages
English (en)
Inventor
Timo Heinrich
Michael Katzer
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2010009920A publication Critical patent/MX2010009920A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen compuestos derivados de azaindol. Los compuestos tienen un núcleo de azaindol opcionalmente sustituido, unido a un anillo carbocíclico que tiene al menos un átomo de nitrógeno y además unido a un anillo arilo opcionalmente sustituido. Se describe un proceso para preparar estos compuestos, composiciones que los comprenden, y métodos para usarlos para tratar desordenes del sistema nervioso central.
MX2010009920A 2008-03-14 2009-02-14 Compuestos de azaindol para tratamiento de trastornos del sistema nervioso central. MX2010009920A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08004860 2008-03-14
PCT/EP2009/001055 WO2009112139A1 (en) 2008-03-14 2009-02-14 Azaindole compounds for treatment of central nervous system disorders

Publications (1)

Publication Number Publication Date
MX2010009920A true MX2010009920A (es) 2010-09-30

Family

ID=40524561

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009920A MX2010009920A (es) 2008-03-14 2009-02-14 Compuestos de azaindol para tratamiento de trastornos del sistema nervioso central.

Country Status (14)

Country Link
US (1) US20110059982A1 (es)
EP (1) EP2250170A1 (es)
JP (1) JP2011517440A (es)
KR (1) KR20100134664A (es)
CN (1) CN101970436A (es)
AR (1) AR070885A1 (es)
AU (1) AU2009225025A1 (es)
BR (1) BRPI0909628A2 (es)
CA (1) CA2718138A1 (es)
EA (1) EA201001425A1 (es)
IL (1) IL207914A0 (es)
MX (1) MX2010009920A (es)
WO (1) WO2009112139A1 (es)
ZA (1) ZA201007325B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103420989B (zh) * 2012-05-15 2016-03-23 华中科技大学 苯并二噁烷类衍生物及其应用
US9598401B2 (en) 2013-07-29 2017-03-21 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use thereof
US9714232B2 (en) 2013-12-20 2017-07-25 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods of use thereof
CN106660489B (zh) * 2014-06-02 2019-07-09 上海延锋金桥汽车饰件系统有限公司 操纵台总成
CN106243088B (zh) 2015-06-03 2019-01-04 广东东阳光药业有限公司 取代的哌嗪化合物及其使用方法和用途
JP6657974B2 (ja) * 2016-01-12 2020-03-04 トヨタ紡織株式会社 金属樹脂一体成形品及びその製造方法
CN107459510B (zh) * 2016-06-06 2021-06-25 华东师范大学 异恶唑类化合物及其应用
CN109574993B (zh) 2017-09-29 2020-12-18 广东东阳光药业有限公司 取代的嘧啶哌嗪化合物及其用途
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
KR102347368B1 (ko) * 2020-11-03 2022-01-07 (주)케이메디켐 신규한 아자인돌 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물
WO2024148274A1 (en) * 2023-01-05 2024-07-11 Apellis Pharmaceuticals, Inc. Complement inhibition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US4954502A (en) * 1988-06-10 1990-09-04 Bristol-Myers Squibb Company 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
CA2043709C (en) * 1990-06-29 2002-01-22 David W. Smith Antimigraine alkoxypyrimidine derivatives
JP2003521443A (ja) * 1998-06-19 2003-07-15 ハー・ルンドベック・アクチエゼルスカベット ４，５，６及び７−インドール及びインドリン誘導体、その製造方法及びその使用方法
US6258819B1 (en) * 1999-08-05 2001-07-10 Syntex (U.S.A.) Llc Substituted 2(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)-4(3H)-azaquinazolinones
CA2395705C (en) * 1999-12-30 2006-10-17 H. Lundbeck A/S Substituted phenyl-piperazine derivatives, their preparation and use
DE10112151A1 (de) * 2001-03-14 2002-09-19 Merck Patent Gmbh Substituierte Benzofuran-2-carbonsäureamide

Also Published As

Publication number Publication date
AU2009225025A1 (en) 2009-09-17
JP2011517440A (ja) 2011-06-09
WO2009112139A1 (en) 2009-09-17
IL207914A0 (en) 2010-12-30
BRPI0909628A2 (pt) 2015-09-22
CA2718138A1 (en) 2009-09-17
CN101970436A (zh) 2011-02-09
EA201001425A1 (ru) 2011-06-30
AR070885A1 (es) 2010-05-12
US20110059982A1 (en) 2011-03-10
KR20100134664A (ko) 2010-12-23
EP2250170A1 (en) 2010-11-17
ZA201007325B (en) 2011-06-29

Similar Documents

Publication Publication Date Title
MX2010009920A (es) Compuestos de azaindol para tratamiento de trastornos del sistema nervioso central.
IL208673A (en) Quinuclidine compounds ligandes for nicotinic alpha-7 acetylcholine receptor
JO3267B1 (ar) بيرولات [3، 4-سي] اوكتاهيدروبيرولو ثنائية الاستبدال كمعدلات لمستقبل اوريكسين
MX2010002312A (es) Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
MX2013011518A (es) 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas para el tratamiento de desordenes del sistema nervioso y cancer.
IN2014DN09805A (es)
PH12012502212A1 (en) Nitrogen heterocyclic compounds usefulas pde10 inhibitors
UA99936C2 (en) Biaryl substituted azabicyclic alkane derivatives
PH12015500211A1 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
WO2014070991A3 (en) Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
WO2011132051A3 (en) Tricycle compounds as phosphodiesterase-10 inhibitors
MX2011010918A (es) Metodo para el tratamiento de trastornos asociados con la actividad de la cinasa de proteina ck2.
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
EP2416795A4 (en) COGNITIVE DECLINE INHIBITORS
WO2012096458A3 (en) Process for preparation of phenyl carbamate derivatives
IN2012DN03846A (es)
TN2012000191A1 (en) Quinuclidine compounds as alpha-7nicotinic acetylcholine receptor ligands
UA104880C2 (uk) Заміщені тетрагідропіранспіропіролідинон і тетрагідропіранспіропіперидинон, спосіб їх одержання й застосування в лікувальних цілях
MY195169A (en) Cyclic Ether Derivatives of Pyrazolo[1,5-A]Pyrimidine-3-Carboxyamide
TW201612169A (en) (R)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
MX2012004317A (es) Com puestos de azabiciclo[2.2.1] heptano como ligandos de receptor de acetilcolina alfa-7-nicotinico.
EP2566856A4 (en) COMPOUNDS AND METHOD FOR TREATING BRAIN DISEASES
WO2013048949A3 (en) Selective nr2b antagonists
MX2018004256A (es) Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.
PH12014502780A1 (en) Azetidine and piperidine compounds useful as pde10 inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal